PARP Inhibitors and Immunotherapy in Gynecologic Cancers
Meeting Series
Meeting Series

PARP Inhibitors and Immunotherapy in Gynecologic Cancers

Novel Therapies to Improve Patient Outcomes

Not a member of My prIME? Join now for instant access.

Don’t miss this meeting in your area! Hear from the experts about current and emerging therapies for gynecologic malignancies. Topics will include PARP inhibition and immunotherapeutic approaches for ovarian, cervical, and endometrial cancers. Attendees will have the opportunity to interact with expert faculty throughout the meeting.

CME

CME

1.0 AMA PRA Category 1 Credit™

CE

CE

1.0 Contact Hour

Aurora, Colorado

Monday, October 1, 2018
12.00 PM – 1.00 PM

Meeting Room 2
The Medical Center of Aurora – South Campus
1501 S Potomac Street
Aurora, Colorado
80012

Robert L. Coleman, MD, FACOG, FACS
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States

Brooklyn, New York

Wednesday, October 31, 2018
1.15 PM – 2.15 PM

1st Floor Conference Room
Maimonides Medical Center – Division of Hematology/Oncology
6300 8th Avenue
Brooklyn, New York
11220

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine-Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona, United States

Fayetteville, North Carolina

Wednesday, October 31, 2018
12.00 PM – 1.00 PM

Cancer Center Conference Room, Basement Level
Cape Fear Valley Health System
1638 Owen Drive
Fayetteville, North Carolina
28304

David O’Malley, MD
The Ohio State University
James Comprehensive Cancer Center
Columbus, Ohio, United States

Pensacola, Florida

Friday, November 2, 2018
12.00 PM – 1.00 PM

BCH Medical Meeting Room – Towers Entrance
Baptist Health Care
1717 North East Street
Pensacola, Florida
32501

David O’Malley, MD
The Ohio State University
James Comprehensive Cancer Center
Columbus, Ohio, United States

Brooklyn, New York

Friday, December 7, 2018
8.00 AM – 9.00 AM

Lecture Hall 1A
SUNY Downstate
395 Lennox Road
Brooklyn, New York
11203

Kathleen Moore, MD
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, Oklahoma, United States

5 min Welcome and introduction
5 min Quick Review: Mechanisms of action and rationale for use of these agents in gynecological malignancies
20 min PARP inhibition and its utility in treating ovarian cancer and endometrial cancer
15 min Immunotherapeutic approaches and their utility in treating gynecological malignancies
5 min Combining PARP inhibitors and checkpoint inhibitors in ovarian cancer treatment: What do we know?
10 min Conclusions, questions, and adjourn

Chair

  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St Joseph's Hospital
    Phoenix, Arizona, United States

Faculty

  • Robert L. Coleman, MD, FACOG, FACSThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Kathleen Moore, MDStephenson Cancer Center
    University of Oklahoma
    Oklahoma City, Oklahoma, United States
  • David O’Malley, MDThe Ohio State University
    James Comprehensive Cancer Center
    Columbus, Ohio, United States
  • Leslie Randall, MD, MASSaddleback Memorial Medical Center
    University of California, Irvine
    Orange, California, United States

*Additional faculty to be confirmed

This activity is intended for gynecologic oncologists, medical oncologists, oncology nurses, and other members of the cancer care team involved in the management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

Physicians:

  • Develop treatment strategies using PARP inhibitors for patients with ovarian cancer
  • Analyze efficacy and safety data on checkpoint inhibitors, alone and in combination with other agents, including PARP inhibitors, for the treatment of ovarian cancer and cervical cancer
  • Discuss efficacy and safety data as well as ongoing clinical trials evaluating checkpoint inhibitors and PARP inhibitors for the treatment of endometrial cancer

Nurses:

  • Describe currently approved targeted therapy options for patients with ovarian cancer
  • Discuss the appropriate use of PARP inhibitors and checkpoint inhibitors for ovarian, endometrial, and cervical cancers, and incorporate strategies to communicate expectations of efficacy and safety to patients

This educational activity is supported by grants from AstraZeneca; Clovis Oncology; Merck and Co, Inc.; and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

prIME Oncology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity has been approved for 1 contact hour.

The criteria for successful completion include attending the full program and completing the evaluation.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.